ICROS

Cancer associated glycan epitopes via Ionic Catch and Release Oligosaccharide Synthesis (ICROS)

Coordinatore	UNIVERSITY OF BRISTOL    more  Organization address address: TYNDALL AVENUE SENATE HOUSE city: BRISTOL postcode: BS8 1TH contact info Titolo: Ms. Nome: Johanna Cognome: Rule Email: send email Telefono: -9288769 Fax: -9250973
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	172˙740 €
EC contributo	172˙740 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2009-IEF
Funding Scheme	MC-IEF
Anno di inizio	2010
Periodo (anno-mese-giorno)	2010-03-01   -   2012-02-29

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITY OF BRISTOL  Organization address address: TYNDALL AVENUE SENATE HOUSE city: BRISTOL postcode: BS8 1TH contact info Titolo: Ms. Nome: Johanna Cognome: Rule Email: send email Telefono: -9288769 Fax: -9250973	UK (BRISTOL)	coordinator	172˙740.80

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The quest for an effective cancer vaccine was initiated over 100 years ago from the moment vaccines against infectious diseases were successfully applied, and despite the many advances to date, the search for therapeutic vaccines derived from carbohydrate antigens is still an ongoing challenge. Carbohydrate antigens of tumour cells are uniquely effective targets for antibody-mediated active and passive cancer immunotherapy and have also proven to be effective targets for immune recognition and attack. The gastrointestinal tract posses a protective epithelial barrier as part of the basic innate protective system, which produces a secreted mucus layer that contains hundreds of different mucin type O-linked oligosaccharides known to be connected with diseases such as breast and colon cancers. However, little is known about the specific role of this family of oligosaccharides in disease due to the lack of tools for study. Access to structurally defined complex carbohydrates is still a very laborious process and combinatorial approaches to prepare diverse libraries of oligosaccharides remain limited. A general automated method for oligosaccharide assembly will allow rapid preparation of structures of interest. This programme’s long term aim is to develop carbohydrate-based cancer vaccines that elicit both a strong humoral- and cellular immune response against colon and breast cancers. To achieve our objectives, we plan to apply a novel and improved methodology (ICROS) to the synthesis of mucin type carbohydrate fragments, which are otherwise not available, ready to be immobilized onto nanocarrier systems for initial biological (antibody screening) and immunogenic assays. The understanding of these glycosylation patterns at both molecular and functional level will help us identify mucin oligosaccharide based antigens that will pave the way to the development of target specific anti cancer vaccines.'